Loading

GenVivo

June 16, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
GenVivo is a private, clinical-stage company with a patented, off-the-shelf vector platform that fights cancer by activating the patient’s own immune system targeting the breadth of the patient’s own tumor antigens. GenVivo’s proprietary platform technology is a non-replicating RNA vector delivered intravenously (or intratumorally), thereby offering significant advantages versus both other vector-based and mRNA immunotherapies. GEN2, GenVivo’s lead clinical candidate now in a US Phase 1/2 clinical trial, designed to stimulate the immune system against all patient-specific tumor antigens—thereby creating a personalizing anti-tumor effect without the time delay and expense associated with some cancer vaccines, which are limited in the number of antigens delivered. GEN-1013 harnesses a potent anti-tumor cytokine delivered via our platform, which enables local expression while avoiding the systemic toxicity associated with other IL-12 therapies. The IND filing is targeted for early 2026.
GenVivo
Company HQ City: San Marino
Company HQ State: CA
Company HQ Country: United States
Year Founded: 2018
Lead Product in Development: GEN2

CEO

David Dornsife

Year Founded

2018

Development Phase of Lead Product

Phase I

Number of Unlicensed Products Looking for Licensing

4

When you expect your next catalyst update?

Readout from expansion arms of GEN2 Phase 1 trial. Approval from FDA to start Phase 1 trial with GEN-1013.

What is your next catalyst (value inflection) update?

December 2025

Website

https://genvivoinc.com/
Primary Speaker
Robert Johnson
Robert Johnson, MD
Chief Operations Officer
GenVivo

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS